Clinical Trial Update: TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension [Phase 1, Phase 2]

View source ↗

Summary

TC-5214 was studied as augmentation therapy for refractory hypertension in a Phase 1/2 trial that has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• TC-5214 (TC-5214)

Snippet

Sponsor: Targacept Inc. | Conditions: Refractory Hypertension | Phase 1, Phase 2 | Status: TERMINATED